Peptide, Protein Or Amino Acid Patents (Class 436/86)
-
Publication number: 20140024123Abstract: Provided is a screening method for a more effective Ras inhibitor. Further provided are amino acid residues at a site important for an interaction with a Ras inhibitor in a Ras polypeptide. By confirming a difference between structural information on the Ras polypeptide by NMR and structural information between a complex of the Ras polypeptide and a seed compound by NMR, a more effective lead compound than the seed compound can be selected. As a result of analysis based on the structural information on the Ras polypeptide by NMR, the amino acid residues capable of interacting with a Ras inhibitor candidate (a) are K5, E37, D38, S39, L56, E63, Y64, A66, M67, Q70, Y71, R73, and T74 with reference to an amino acid sequence set forth in SEQ ID NO: 1.Type: ApplicationFiled: January 31, 2012Publication date: January 23, 2014Applicant: NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITYInventors: Tohru Kataoka, Fumi Shima, Atsuo Tamuta, Mitsugu Araki
-
Publication number: 20140024051Abstract: The present invention provides methods and compositions for identifying fatigue, disease states associated with fatigue, recovery from fatigue and/or physical performance capability in a subject.Type: ApplicationFiled: March 15, 2013Publication date: January 23, 2014Applicant: Hyperion BiotechnologyInventor: Hyperion Biotechnology
-
Publication number: 20140024120Abstract: A dye binding method for protein analysis is disclosed. The method includes the steps of preparing an initial reference dye solution of unknown concentration from an initial reference dye concentrate and creating an electronic signal based upon the absorbance of the initial reference dye solution. Thereafter, an electronic signal is created based upon the absorbance of a dye filtrate solution prepared from the initial reference dye solution and an initial protein sample. The absorbance signals from the reference dye solution and the dye filtrate solution are sent to a processor that compares the respective absorbances and calculates the protein content of the protein sample based upon the difference between the absorbances.Type: ApplicationFiled: September 27, 2013Publication date: January 23, 2014Applicant: CEM Corp.Inventors: Michael J Collins, Sr., Joseph J Lambert, Timothy A Zawatsky, David L Herman
-
Patent number: 8633034Abstract: This invention relates to methods for evaluating or inhibiting the aggregation of a protein in an aqueous suspension including organopolysiloxane and medical articles coated with organopolysiloxane containing a protein solution including sugar and a non-ionic surfactant.Type: GrantFiled: October 22, 2008Date of Patent: January 21, 2014Assignees: Becton, Dickinson and Company, The Regents of the University of ColoradoInventors: Joseph T. Trotter, Jean-Bernard Hamel, John Frank Carpenter, Theodore Randolph, John Paul Gabrielson
-
Patent number: 8633031Abstract: In various aspects, the present teachings provide systems, methods, assays and kits for the absolute quantitation of protein expression. In various aspects, the present teachings provide methods of determining the concentration of one or more proteins of interest in one or more samples of interest. In various aspects, the present teachings provide methods of determining the absolute concentration of one or more isoforms of a protein using standard samples of signature protein fragments and parent-daughter ion transition monitoring (PDITM). In various embodiments, the absolute concentration of multiple isoforms of a biomolecule in a sample, multiple proteins in a biological process, a combination of multiple samples, or combinations thereof, can be determined in a multiplex fashion using the present teachings. In various aspects, provided are methods of assessing the response of a biological system to a chemical agent.Type: GrantFiled: September 30, 2009Date of Patent: January 21, 2014Assignee: DH Technologies Development Pte. Ltd.Inventor: Christine L. Hunter
-
Publication number: 20140017797Abstract: This invention concerns isotopically coded or non-isotopically coded affinity-tags for analysis of certain target molecules in complex samples, in particular for mass spectrometric analysis of proteomic samples. The affinity-tags have the following general formula X-SPACER-OPO3H2, wherein X is a functional group or moiety capable of reacting with a functional group of a protein, peptide, DNA, lipid, sugar and/or steroid. These phosphate affinity tags (‘PTAG’) are capable of high but reversible binding to metal-oxides like TiO2. Due to this property, tagged sample fractions can be isolated from non-tagged sample fraction by affinity chromatography. The binding of organophosphate to metal-oxides remains intact during multiple washings of preferably acidic solutions to remove non-specifically bound components. PTAG's are also envisaged wherein X is selected such that it is capable of binding proteins, peptides, nucleic acid molecules, lipids, carbohydrates, steroids and the like.Type: ApplicationFiled: December 13, 2011Publication date: January 16, 2014Applicant: De Staadt der Nederlanden, vert doorde minister van VWSInventor: Jamila Willhelmina Zomer-Elhadari
-
Publication number: 20140017716Abstract: Compositions and methods are provided for the rapid and efficient denaturation and degradation of protein samples. The compositions and methods produce samples that can readily be analyzed by, for example, mass spectrometry. Unwanted dilution of the sample is avoided and the samples and methods are amenable for use with robotic laboratory sample handling instruments. The compositions and methods surprisingly provide significantly improved reproducibility and accuracy of the resulting mass spectrometric analyses.Type: ApplicationFiled: July 11, 2013Publication date: January 16, 2014Inventor: N. Leigh ANDERSON
-
System and method for quantifying fragile X mental retardation 1 protein in tissue and blood samples
Patent number: 8628934Abstract: A system and method for the detection and quantification of fragile X mental retardation protein (FMRP) in human tissue and blood samples. The system includes several high avidity monoclonal antibodies that may be provided on Xmap microspheres to capture FMRP from a tissue or blood specimen. The resulting complex is reacted with a polyclonal anti-FMRP rabbit antibody and then mixed with an anti-rabbit IgG antibody conjugated to phycoerythrin. Fluorescence emitted from the resulting complex is a function of the amount of FMRP present in the specimen.Type: GrantFiled: June 11, 2012Date of Patent: January 14, 2014Assignee: The Research Foundation For Mental Hygiene, Inc.Inventors: Giuseppe LaFauci, William T. Brown, Richard Kascsak -
Patent number: 8628727Abstract: The present invention relates to compositions, devices and methods for detecting microorganisms (e.g., anthrax). In particular, the present invention provides portable, surface-enhanced Raman biosensors, and associated substrates, and methods of using the same, for use in rapidly detecting and identifying microorganisms (e.g., anthrax).Type: GrantFiled: August 28, 2007Date of Patent: January 14, 2014Assignee: Northwestern UniversityInventors: Richard P. Van Duyne, Xiaoyu Zhang, Jing Zhao, Alyson V. Whitney, Jeffrey W. Elam, George C. Schatz, Peter C. Stair, Shengli Zou, Matthew Young, Olga Lyandres
-
Patent number: 8628724Abstract: Methods and systems to collect a sample of bodily fluid from a patient using an integrated needle and test strip assembly are provided. In this novel assembly, the test strip and needle form one unit that captures the sample of blood or interstitial fluid from the patient once the apparatus is pressed to the skin. The hollow aspiration needle includes more than one opening at a distal end, each opening coming into contact with the bodily fluid when disposed within a cutaneous or subcutaneous layer of the patient's skin. The disclosed test strip includes at least one reaction site for testing analyte concentrations and a means for linking to many commercially available test strip meters to provide readout of the analyte concentration. The sample may be captured by capillary flow, by an integrated aspirator, or by a differential vacuum device resident on the test strip meter.Type: GrantFiled: January 3, 2012Date of Patent: January 14, 2014Assignee: Charleston Area Medical Center, Inc.Inventor: J. Todd Kuenstner
-
Patent number: 8628973Abstract: The invention relates to a method of determining feline or canine proBNP or fragments thereof, comprising the steps of providing a feline or canine sample, contacting the sample with at least one antibody which, when determining feline proBNP, or fragments thereof, respectively, binds to at least one epitope in the region comprising the amino acids 20 to 42 and/or in the region comprising the amino acids 57 to 80 of feline proBNP and, when determining canine proBNP, or fragments thereof, binds to at least one epitope in the region comprising the amino acids 20 to 86 of canine proBNP, and determining the presence and/or concentration of the feline or canine proBNP, or fragments thereof, present in the sample.Type: GrantFiled: September 8, 2005Date of Patent: January 14, 2014Assignee: Biomedica Medizinprodukte GmbH & Co KGInventors: Wolfgang Woloszczuk, Gerhard Hawa
-
Publication number: 20140011282Abstract: The present invention generally relates to a low temperature plasma probe for desorbing and ionizing at least one analyte in a sample material and methods of use thereof. In one embodiment, the invention generally relates to a low temperature plasma probe including: a housing having a discharge gas inlet port, a probe tip, two electrodes, and a dielectric barrier, in which the two electrodes are separated by the dielectric barrier, in which application of voltage from a power supply generates a low temperature plasma, and in which the low temperature plasma is propelled out of the discharge region by the electric field and/or the discharge gas flow.Type: ApplicationFiled: August 26, 2013Publication date: January 9, 2014Applicant: PURDUE RESEARCH FOUNDATIONInventors: Zheng Ouyang, Jason Harper, Nicholas Charipar, Robert Graham Cooks
-
Publication number: 20140011191Abstract: The present invention relates to devices and methods for measuring the quantity of multiple analytes in a sample. The device is designed such that each of the analyte sensing elements is configured to measure the quantity of a predetermined analyte and where the machine executable instructions are configured to select the proper analyte sensing element corresponding to the analyte to be measured.Type: ApplicationFiled: September 4, 2013Publication date: January 9, 2014Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: Matthew Beaudet, Jill Hendrickson, David Hagen, Rich Meyer
-
Patent number: 8623654Abstract: An object of the present invention is to provide a control material which can be preferably employed in detection of 1,5-anhydro-D-glucitol and glycoalbumin, which are employed as excellent indices for diabetes. The present inventor has found that mannitol which is added to serum or plasma used as control material stabilizes 1,5-anhydro-D-glucitol and glycoalbumin present in the serum or plasma for a long period of time, and that the object can be attained through provision of (1) an agent for stabilizing control material, the agent being composed of mannitol and (2) control material containing mannitol and 1,5-anhydro-D-glucitol.Type: GrantFiled: March 4, 2010Date of Patent: January 7, 2014Assignee: BML, Inc.Inventor: Isami Tsuboi
-
Patent number: 8617838Abstract: The invention includes fusion polypeptides including a first fluorescent protein, e.g., a FRET donor protein, a second fluorescent protein, e.g., a FRET acceptor protein, and, linked to at least one of the fluorescent (e.g., FRET donor or FRET acceptor) proteins, an Fc-region of an immunoglobulin. The polypeptide can be immobilized with respect to a surface via the Fc-region even in the absence of antibodies to either the FRET donor protein or FRET acceptor protein, and can be used as a calibration standard for fluorescence resonance energy transfer includes a polypeptide.Type: GrantFiled: September 20, 2005Date of Patent: December 31, 2013Assignee: University of MassachusettsInventors: Eicke Latz, Brian G. Monks, Douglas T. Golenbock
-
Publication number: 20130344079Abstract: A method of diagnosing Phenylketonuria (PKU) in a subject in need thereof is disclosed. The method comprises detecting phenylalanine fibrils in a tissue of the subject, wherein a presence or level above a predetermined threshold of said phenylalanine fibrils in said tissue, is indicative of PKU in the subject. Antibodies capable of detecting phenylalanine fibrils are also disclosed as well as additional uses.Type: ApplicationFiled: March 8, 2012Publication date: December 26, 2013Applicant: Ramot at Tel-Aviv University Ltd.Inventors: Lihi Adler-Abramovich, Ohad Carny, Ehud Gazit
-
Publication number: 20130344523Abstract: An agent for searching for protein crystallization conditions, containing a water-swellable layered silicate having a fluorine atom and a hydroxyl group, wherein the fluorine atom is covalently bonded to the silicate by isomorphous substitution with the hydroxyl group. A method of searching for protein crystallization conditions, which comprises a step of mixing the agent for searching for protein crystallization conditions described above and a solution in which a protein is dissolved.Type: ApplicationFiled: March 29, 2012Publication date: December 26, 2013Applicants: TOKYO UNIVERSITY OF SCIENCE EDUCATIONAL FOUNDATION ADMINISTRATIVE ORGANIZATION, KUNIMINE INDUSTRIES CO., LTD.Inventors: Keiichi Kurosaka, Munehiro Kubota, Kengo Sakaguchi, Keita Ino, Itsumi Udagawa, Kazuki Iwabata, Yoichi Takakusagi, Yasutaka Seki
-
Patent number: 8613907Abstract: Disclosed are compositions and methods for reducing the proliferation of cancer cells through targeted interactions with integrins.Type: GrantFiled: March 17, 2003Date of Patent: December 24, 2013Assignee: University of RochesterInventors: Hartmut Land, Laurent Deleu
-
Publication number: 20130337445Abstract: A method and apparatus for the discovery, development and clinical application of multiplex synthetic assays based on patterns of free radicals, indicators of oxidative or nitrosative stress, or indicators of the redox state of biologic fluids and tissue specimens. These individual measurements are combined into an optimized clinical biomarker using known well-known mathematical, machine learning techniques.Type: ApplicationFiled: June 19, 2013Publication date: December 19, 2013Inventor: Norman A. Paradis
-
Patent number: 8609423Abstract: The present invention provides methods and compositions for labeling, separating and analyzing proteins, particularly a specific protein of interest within a cell lysate or in a mixture of proteins. The proteins are labeled with an amine reactive or thiol reactive fluorescent dye, or an amine reactive fluorogenic reagent that becomes fluorescent upon reacting to amine groups located on the protein. Following the labeling step, the proteins within the mixture can be separated and analyzed. In a further embodiment, a tag binding fluorogenic reagent that can bind to a tag on a tagged protein is added to specifically label the protein of interest.Type: GrantFiled: May 16, 2008Date of Patent: December 17, 2013Assignee: Life Technologies CorporationInventors: Thomas Diller, George Hanson, Bethany Sutton, Timothy Updyke
-
Patent number: 8609424Abstract: Disclosed is a novel high-sensitive ProGRP measurement method, which is free from problems such as the fluctuations in measurement values and the operational constraints (e.g., the constraints on the handling of a sample). Specifically disclosed is a method for the measurement of a gastrin-releasing peptide precursor and/or a digested product thereof using at least two different antibodies each of which can recognize an epitope represented by the amino acid sequence consisting of amino acid 47 to amino acid 68 of the amino acid sequence set forth in SEQ ID NO:1. The method can detect a ProGRP or a digested product thereof in a refrigerated sample within a shorter period, by using the sample in a smaller amount, and with a higher degree of detective sensitivity, compared with the conventional methods.Type: GrantFiled: September 29, 2008Date of Patent: December 17, 2013Assignee: Advanced Life Science Institute, Inc.Inventors: Katsumi Aoyagi, Yukiji Izawa
-
Patent number: 8609437Abstract: Compositions and methods for use in methods and kits for the detection of an increased risk of pancreatic cancer are provided. Cyst fluid samples isolated from patients that are positive for at least three of the following markers, mucin 1, mucin 2, mucin 5AC, mucin 5B, mucin 6, CEA CAM 1, CEACAM 5, CEACAM 6, CEACAM 7, CEACAM 8, S100-A6, S100-A8, S100-A9 and S100-A11 indicate that such patients are at greater risk for the development of pancreatic cancer when compared to cyst fluid samples isolated from patients lacking these markers.Type: GrantFiled: January 21, 2009Date of Patent: December 17, 2013Assignee: The Institue for Cancer ResearchInventors: Anthony T. Yeung, Jeffrey Tokar
-
Publication number: 20130330830Abstract: A method for fluorescence detection is provided and includes mixing a fluorescence detecting reagent into a sample, placing the sample into a sample tray, where the sample tray includes at least a row of blank slots and at least a row of sampling slots. Then, exposing the sample tray to a background light, and obtaining a grayscale background image of the sample tray.Type: ApplicationFiled: May 31, 2013Publication date: December 12, 2013Inventors: Ping-Hua TENG, Ching-Ko LIN, Hung-Ming CHEN
-
Publication number: 20130331327Abstract: This invention relates to the specific Asp76Asn (D76N) variant ?2-microglobulin (?2M) protein, nucleic acids encoding the same, their characterization and applications in studying amyloid fibrillogenesis, including diagnostic and therapeutic applications.Type: ApplicationFiled: June 8, 2012Publication date: December 12, 2013Inventors: Vittorio Bellotti, Sophie Valleix, Mark Brian Pepys, Madeleine M. Riès-Kautt
-
Patent number: 8603829Abstract: A method is provided for diagnosing or predicting atherosclerosis with the use of, as indicators, markers (factors) that allow early detection and progression prediction of the disease and a method for evaluating preventive or therapeutic effects. In one form, the present method includes detecting CD166 (ALCAM) level in a sample of a subject such as human. Another aspect of the present method includes evaluating preventive or therapeutic effects of a compound on atherosclerosis. A kit and an apparatus for carrying out such methods is also provided.Type: GrantFiled: August 10, 2010Date of Patent: December 10, 2013Assignee: Hitachi Ltd.Inventors: Yuji Kuge, Hiroko Hanzawa, Takeshi Sakamoto, Naomi Manri
-
Patent number: 8603830Abstract: The present invention relates to a method for the determination of polysorbate in a protein-containing sample. The method of the present invention involves the pretreatment of the sample by alkaline hydrolysis followed by colorimetric determination.Type: GrantFiled: March 1, 2012Date of Patent: December 10, 2013Assignees: Baxter International Inc., Baxter Healthcare SAInventors: Alfred Weber, Andrea Engelmaier, Heinz Anderle, Hans-Peter Schwarz
-
Patent number: 8603758Abstract: A method of detecting prostate tumorigenesis in a subject, the method including the steps of (a) obtaining a sample from the prostate of the human subject, (b) detecting quantitatively or semi-quantitatively in the sample a level of expression for PKC-? and (c) comparing the expression level in (b) to a level of expression in a normal control, wherein overexpression of PKC-?, with respect to the control, indicates the presence of prostate cancer in the subject. The present invention is based upon the discovery that PKC-? levels are elevated during prostate tumorigenesis. Furthermore, the proliferation rate of the tumor correlates with the level of PKC-?. The invention also provides methods of treating prostate cancer by administering to the subject a compound that inhibits the expression of PKC-?. The compound can be a small interfering RNA (siRNA) molecule.Type: GrantFiled: June 25, 2012Date of Patent: December 10, 2013Assignees: University of South Florida, The United States of America as represented by the Department of Veterans AffairsInventors: Mildred Acevedo-Duncan, Hla Y. Win, Raoul Salup
-
Publication number: 20130324523Abstract: An object of the present invention is to provide a probe for imaging a ?-sheet structure protein which can be used for the diagnosis of conformational diseases, particularly disease (tauopathy) having a cardinal symptom such as intracerebral accumulation of tau protein, for example, Alzheimer's disease. Another object of the present invention is to provide a compound which is highly specific to tau and can image tau with satisfactory sensitivity, and also has high brain transition, low or non-recognized bone-seeking properties and low or non-recognized toxicity. According to the present invention, the above problems are solved by providing a compound of a formula I (wherein A, R1, R2, R3, R4, R5, R6, Ra and Rb are as defined in the present description) or a pharmaceutically acceptable salt or solvate thereof.Type: ApplicationFiled: October 28, 2011Publication date: December 5, 2013Applicant: CLINO LTD.Inventors: Yukitsuka Kudo, Shozo Furumoto, Nobuyuki Okamura
-
Patent number: 8597958Abstract: This invention pertains to methods and compositions for the diagnosis and treatment of cardiovascular conditions. More specifically, the invention relates to isolated molecules that can be used to diagnose and/or treat cardiovascular conditions including cardiac hypertrophy, myocardial infarction, stroke, arteriosclerosis, and heart failure.Type: GrantFiled: June 1, 2011Date of Patent: December 3, 2013Assignee: The Brigham and Women's Hospital, Inc.Inventor: Richard T. Lee
-
Patent number: 8597955Abstract: The invention relates to a peptide and retro or retro-inverso peptide thereof, with a length of ?25 amino acid residues, characterized in that the peptide comprises at least one citrulline residue, and exhibits a sequence identity over the whole sequence of the peptide of ?70% compared to human hnRNP A3 protein (SEQ ID No. 1) and uses thereof.Type: GrantFiled: December 23, 2009Date of Patent: December 3, 2013Assignee: Charite—Universitatsmedizin BerlinInventors: Karl Skriner, Kerstin Adolph, Jørg Hollidt
-
Patent number: 8597878Abstract: A reaction unit containing a bottom part and a top part for pipetting a liquid, wherein the bottom part contains a reaction cavity with a permeable filter grid insert and the top part contains a reaction cavity which can be fixed on said bottom part and contains a cavity or covering for receiving a magnet.Type: GrantFiled: May 6, 2008Date of Patent: December 3, 2013Assignees: AJ Innuscreen GmbH, AJ Cyberton Gesellschaft fuer Laborautomationssysteme MbhInventors: Timo Hillebrand, Matthias Arndt, Uwe Wellnitz, Klaus Berka, Volker Hillebrand
-
Patent number: 8597954Abstract: The present invention relates to a stool sample processing method and stool sample processing container the a stool sample processing container provided with a stool collection tool, a suspending solution holding portion and a processing solution holding portion, wherein stool sample preparation solutions consisting of a suspending solution and a stool sample processing solution are respectively housed in a suspending solution holding container and a processing solution holding container, after first mixing a stool sample with the suspending solution and suspending therein, a sealant is released into the suspending solution holding container by pressing on the lower portion of the processing solution holding container, and the resulting stool suspension mixes with the stool sample processing solution that stabilizes the nuclide acid.Type: GrantFiled: November 11, 2010Date of Patent: December 3, 2013Assignee: Olympus CorporationInventors: Yasuo Tanigami, Kazue Nakajima, Takami Shibazaki
-
Method for manufacturing mesoporous materials, materials so produced and use of mesoporous materials
Patent number: 8597682Abstract: The present invention relates to a new synthetise for the preparation of mesoporous structures including mesoporous materials with chiral morphologies and mesoporous materials with local or surface chirality. The method can be used for manufacturing controlled drug delivery devices, for example for delivery of folic acid, and fluorescent particles.Type: GrantFiled: February 11, 2009Date of Patent: December 3, 2013Assignee: Nanologica ABInventor: Alfonso Garcia-Bennett -
Patent number: 8592170Abstract: A high molecular weight form of Ngal is provided which can be used to diagnose chronic kidney disease. High molecular weight Ngal is about 75 kDa to about 350 kDa, and comprises non-Ngal proteins, such as polymeric immunoglobulin receptor, alpha-2-macroglobulin and immunoglobulin heavy chain. Methods are disclosed for assessing high molecular weight Ngal in a diagnostic sample from a subject.Type: GrantFiled: March 12, 2009Date of Patent: November 26, 2013Assignee: The Trustees of Columbia University in the City of New YorkInventors: Jonathan Barasch, Nicholas Barasch
-
Patent number: 8592217Abstract: The invention is directed to droplet actuator devices and assay methods. The invention includes assay methods of conducting an assay comprising combining a sample with an umbelliferyl derivative, wherein the sample potentially comprises an enzyme capable of cleaving the umbelliferyl derivative and where the umbelliferyl derivative comprises an umbelliferyl core modified with one or more modifying moieties.Type: GrantFiled: January 10, 2013Date of Patent: November 26, 2013Assignee: Advanced Liquid Logic, Inc.Inventor: Allen E. Eckhardt
-
Patent number: 8592216Abstract: The present invention provides methods for enhancing the fragmentation of peptides for mass spectrometry by modifying the peptides with a tagging reagent containing a functional group, such as a tertiary amine, having a greater gas-phase basicity than the amide backbone of the peptide. These high gas-phase basicity functional groups are attached to a peptide by reacting the tagging reagent to one or more available carboxylic acid groups of the peptide. Linking these high gas-phase functional groups to the peptides leads to higher charge state ions from electrospray ionization mass spectrometry (ESI-MS), which fragment more extensively during fragmentation techniques, particularly non-ergodic fragmentation techniques such as electron capture dissociation (ECD) and electron transfer dissociation (ETD).Type: GrantFiled: April 14, 2010Date of Patent: November 26, 2013Assignee: Wisconsin Alumni Research FoundationInventors: Brian L. Frey, April L. Jue, Casey J. Krusemark, Lloyd M. Smith, Joshua J. Coon
-
Publication number: 20130309774Abstract: A set of two or more types of isobaric tags is described where each tag in the set includes a mass-labeling group and a mass-normalizing group. The mass-labeling group includes a reactive group configured to form a first bond to a functional group of an analyte. The mass-normalizing group is attached to the mass-labeling group via a second bond. The first bond is configured to be stable when subjected to a dissociative energy level from a mass spectrometer so that the first bond does not cleave. When subjected to the same dissociative energy level, the second bond is configured to cleave that liberates the mass-normalizing groups. The tag is configured to form a charged mass-labeled analyte when the second bond is cleaved.Type: ApplicationFiled: May 18, 2012Publication date: November 21, 2013Inventors: Vladimir ZABROUSKOV, John C. ROGERS
-
Patent number: 8586369Abstract: The invention pertains generally to novel compositions and methods for constructing chemically sensitive ion channels. The compositions and methods include, for example, novel gramicidin A derivatives and their use in constructing novel ion channels for use as biosensors.Type: GrantFiled: July 9, 2008Date of Patent: November 19, 2013Assignee: The Regents of the University of CaliforniaInventors: Jerry Yang, Steven Blake, Michael Mayer
-
Patent number: 8586370Abstract: There is provided a chimeric protein of capsid protein of Hepatitis B virus (HBV) and B domain of Staphylococcal protein A (SPAB); a method for fabricating the same; the substrate and nanosensor immobilized with HBV-derived chimeric protein; and the use of the above nanosensor.Type: GrantFiled: September 2, 2011Date of Patent: November 19, 2013Assignee: Korea University Research and Business FoundationInventors: Jee Won Lee, Young Keun Kim, Moon Kyu Cho, Jin Seung Park, Eun Jung Lee
-
Patent number: 8586380Abstract: Methods using mass spectral data analysis and a classification algorithm provide an ability to determine whether a non-small-cell lung cancer patient, head and neck squamous cell carcinoma or colorectal cancer patient has likely developed a non-responsiveness to treatment with a drug targeting an epidermal growth factor receptor pathway. As the methods of this disclosure require only simple blood samples, the methods enable a fast and non-intrusive way of measuring when drugs targeting the EGFR pathway cease to be effective in certain patients. This discovery represents the first known example of true personalized selection of these types of cancer patients for treatment using these classes of drugs not only initially, but during the course of treatment.Type: GrantFiled: December 7, 2011Date of Patent: November 19, 2013Assignee: Biodesix, Inc.Inventors: Heinrich Röder, Maxim Tsypin, Julia Grigorieva
-
Patent number: 8586379Abstract: Methods using mass spectral data analysis and a classification algorithm provide an ability to determine whether a non-small-cell lung cancer patient, head and neck squamous cell carcinoma or colorectal cancer patient has likely developed a non-responsiveness to treatment with a drug targeting an epidermal growth factor receptor pathway. As the methods of this disclosure require only simple blood samples, the methods enable a fast and non-intrusive way of measuring when drugs targeting the EGFR pathway cease to be effective in certain patients. This discovery represents the first known example of true personalized selection of these types of cancer patients for treatment using these classes of drugs not only initially, but during the course of treatment.Type: GrantFiled: December 7, 2011Date of Patent: November 19, 2013Assignee: Biodesix, Inc.Inventors: Heinrich Röder, Maxim Tsypin, Julia Grigorieva
-
Publication number: 20130303732Abstract: The invention provides a method for controlling contaminants in biopharmaceutical purification processes by using light scattering and UV absorbance to establish a determinant. The invention makes use of multi-angle light scattering (MALS) and UV as a continuous monitoring system to provide information about the elution peak fractions in real-time instead of conventional pooling methods that rely on a predetermined percent UV peak max value to initiate the pooling process; regardless of product quality.Type: ApplicationFiled: March 26, 2013Publication date: November 14, 2013Inventors: Arthur C. Hewig, III, Duke H. Phan, Yinges Yigzaw, Robert Bailey
-
Publication number: 20130302328Abstract: This disclosure provides ten (10) specific peptides, and particular peptide characteristics, from the cell membrane-bound Her2 protein and a diagnostic assay useful for determining the presence and amount of full length and truncated versions of the full-length Her2 protein in cells derived from formalin fixed paraffin embedded tissue.Type: ApplicationFiled: December 8, 2011Publication date: November 14, 2013Applicant: Expression Pathology, Inc.Inventor: David Krizman
-
Patent number: 8580491Abstract: The present invention relates to a method for diagnosing cancer using information on the aberrant glycosylation of a glycoprotein. More precisely, the present invention relates to a cancer diagnosis peptide marker, which is screened by: a step of separating, using a lectin, a glycoprotein which is aberrantly glycosylated in accordance with the occurrence of cancer; and a step of selecting a hydrolyzed peptide marker derived from the aberrantly glycosylated glycoprotein by observing the quantitative changes in the separated glycoprotein. The present invention also relates to a method for diagnosing cancer using the peptide marker as an agent.Type: GrantFiled: December 24, 2010Date of Patent: November 12, 2013Assignee: Korea Basic Science InstituteInventors: Yeong Hee Ahn, Jong Shin Yoo
-
Publication number: 20130295679Abstract: A method of predicting a SGA infant in a patient at a pre-symptomatic gestational stage is described. The method comprises a step of assaying a biological sample from the patient for an abundance of a plurality of metabolite biomarkers selected from the 19 metabolite biomarkers of Table IV, correlating the abundance of the plurality of metabolite biomarkers with a metabolite fingerprint of SGA shown in Table IV, and predicting SGA based on the level of correlation between the abundance of the plurality of metabolite biomarkers and the metabolite fingerprint of Table IV.Type: ApplicationFiled: November 16, 2011Publication date: November 7, 2013Applicant: UNIVERSITY COLLEGE CORK - NATIONAL UNIVERSITY OF IRELAND, CORKInventors: Louise Kenny, Philip Baker
-
Publication number: 20130295095Abstract: The invention relates to binding molecules capable of specifically recognizing soluble oligomers of N-terminal truncated A? starting with pyroglutamate (A??E), pharmaceutical compositions comprising same, and their respective therapeutic uses. Particularly, the invention relates to an antibody molecule capable of specifically recognizing A? oligomers, wherein said antibody binds and/or detects an epitope as bound and/or detected by antibody PG3-38 9D5H6 as deposited under DSM AC-C3056.Type: ApplicationFiled: June 3, 2011Publication date: November 7, 2013Inventors: Thomas Bayer, Oliver Wirths, Henrik Martens, Christian Erck
-
Patent number: 8574915Abstract: Provided are methods for determining the amount of thyroglobulin in a sample using various purification steps followed by mass spectrometry. The methods generally involve purifying thyroglobulin in a test sample, digesting thyroglobulin to form peptide T129, purifying peptide T129, ionizing peptide T129, detecting the amount of peptide T129 ion generated, and relating the amount of peptide T129 ion to the amount of thyroglobulin originally present in the sample.Type: GrantFiled: April 9, 2013Date of Patent: November 5, 2013Assignee: Quest Diagnostics Investments IncorporatedInventors: Yanni Zhang, Nigel J. Clarke, Richard E. Reitz
-
Publication number: 20130288386Abstract: An article comprising: an array of calorimeter devices, wherein the device comprises: at least one fluidic enclosure disposed on a microfluidic chip, wherein the fluidic enclosure is substantially gas impermeable; at least one first chamber and at least one second chamber, wherein the first chamber and the second chamber are disposed within and enclosed by the fluidic enclosure, wherein the first chamber and the second chamber are not vacuum encapsulated; at least two microfluidic channels connected to the first chamber and at least two microfluidic channels connected to the second chamber; and at least one thermal sensor disposed between the chip and the first and second chambers, wherein the thermal sensor is adapted to measure a temperature differential between the first and second chambers. Examples include DSC and TSA devices. Biological binding and melting experiments can be done with high sensitivity.Type: ApplicationFiled: March 15, 2013Publication date: October 31, 2013Inventors: Chung Wah FON, Michael L. ROUKES
-
Publication number: 20130288232Abstract: The present invention relates to a method and an apparatus for a fast thermo-optical characterisation of particles. In particular, the present invention relates to a method and a device to measure the stability of (bio)molecules, the interaction of molecules, in particular biomolecules, with, e.g. further (bio)molecules, particularly modified (bio)molecules, particles, beads, and/or the determination of the length/size (e.g. hydrodynamic radius) of individual (bio)molecules, particles, beads and/or the determination of length/size (e.g. hydrodynamic radius).Type: ApplicationFiled: April 26, 2013Publication date: October 31, 2013Inventors: Stefan Duhr, Philipp Baaske
-
Patent number: 8569071Abstract: The present teachings provide methods for analyzing one or more amine-containing compounds in one or more samples using isobaric labels and parent-daughter ion transition monitoring (PDITM). In various embodiments, the methods comprise the steps of: (a) labeling one or more amine-containing compounds with different isobaric tags from a set of isobaric tags, each isobaric tag comprising a reporter ion portion; (b) combining at least a portion of each of the isobarically labeled amine-containing compounds to produce a combined sample; (c) subjecting at least a portion of the combined sample to PDITM; (d) measuring the ion signal of one or more of the transmitted reporter ions; and (e) determining the concentration of one or more of the isobarically labeled amine-containing compounds based at least on a comparison of the measured ion signal of the corresponding reporter ion to one or more measured ion signals of a standard compound.Type: GrantFiled: September 8, 2009Date of Patent: October 29, 2013Assignee: DH Technologies Development Pte. Ltd.Inventors: Subodh B. Nimkar, Subhasish Purkayastha, Darryl Pappin, Scott Daniels